Ampio study: Ampion inhibits key inflammatory pathway in COVID-19 and lupus nephritis

ENGLEWOOD -- Ampio Pharmaceuticals (NYSE American: AMPE) announced results of a pre-clinical study demonstrating Ampion inhibits an important pro-inflammatory pathway in the types of immune cells... Read More

Friday April 9, 2021 0 comments Tags: Englewood, Ampio Pharmaceuticals, Ampion, COVID-19, lupus nephritis, Dr. David Bar-Or